Brian Kotzin

Brian Kotzin is Senior Vice President, Clinical Development, at Nektar Therapeutics. He has more than 30 years of experience in the fields of inflammation and immunology in academia and industry, and expertise in various autoimmune and inflammatory diseases, including systemic lupus erythematosus, rheumatoid arthritis and psoriasis.

Prior to joining Nektar, Brian served as Vice President of Global Clinical Development and Head of the Inflammation Therapeutic Area at Amgen. During his 11 years at Amgen, he also served as Vice President of Translational Sciences and Head of Medical Sciences/Early Development, where he was responsible for the planning and execution of early-phase clinical development in all therapeutic areas as well as the discovery and implementation of pharmacodynamic biomarkers in clinical studies and clinical immunology support for clinical studies.

Prior to entering the life sciences industry, he held several positions as a professor at the University of Colorado Health Sciences Center, where his research focused on immunopathogenesis of disease. Brian has held leadership roles at several national organizations, including as a member of the American College of Rheumatology (ACR) Board of Directors, Member and Chairperson of the NIH Immunological Sciences Study Section, Chairperson of the NIH Autoimmunity Centers of Excellence, and Member of the Board of Directors for the Federation of Clinical Immunology Societies. He is currently an elected Master of the ACR. Brian is a Board of Directors member at Rigel and Progenity.

Brian received a doctorate in medicine from Stanford University and a bachelor’s degree in mathematics from the University of Southern California.